ALSUntangled 48: Perampanel (Fycompa)

Perampanel (Fycompa)

INTRODUCTION Epilepsy is a serious neurological condition that affects more than 50 million individuals globally, 80% of whom live in developing countries.1,2 An estimated 1.7% of U.S. adults have been diagnosed with the condition.3 From prominent historical fi gures, such as Julius Caesar and Vladimir Lenin, to friends or family members, most people probably know someone affected by epilepsy.2...

ALSUntangled No. 22: Propofol.

ISSN 2167-8421 print/ISSN 2167-9223 online © 2013 Informa Healthcare DOI: 10.3109/21678421.2013.826469 neuroinfl ammation (18,19) occur in ALS, although attempts to manipulate these events have not yet shown clear benefi ts in human ALS trials. Propofol has a short half-life; once infusion is stopped, its clinical effects last only minutes (3). For this reason, it is diffi cult to understand ho...

ALSUntangled No. 34: GM604

ALSUntangled update 4: investigating the XCell-Center.

ALSUntangled No. 11: Nu Tech Mediworld.

Now 26 months old, ALSUntangled (www.alsuntangled. org) investigates alternative and off-label treatment options in ALS using social networking tools. Our twitter and NING memberships continue to grow. To date we have published 10 investigations on 11 different alternative and off-label treatment options, collaborating with Quackwatch (www. quackwatch.org), Patients Like Me (www.patients likeme...